

---

*Italicized page numbers are those with illustrations and/or photos.*

- access  
 iv, 43, 125, 126, 139, 140, 141, 158,  
 177, 191, 197, 207, 234, 235, 237,  
 243, 249–50, 253–258, 258, 295
- ACT UP  
 220, 275, 280, 281–282, 325, 327
- adenovirus  
 48, 58, 290, 325, 327, 345
- adeno-associated virus (AAV)  
 49, 327, 345
- adjuvant  
 48, 327, 345
- Adolescent Medicine Trials Network  
 for HIV/AIDS Interventions (ATN)  
 203
- adolescents  
 174, 198, 199–217, 250, 257, 276
- adverse event  
 adverse reaction  
 91, 93, 95, 97, 98–100, 345
- Africa Centre  
 130
- African AIDS Vaccine Programme  
 (AAVP)  
 69, 246
- African Americans  
 201–202, 223, 299, 300, 302
- AIDES  
*i–ii*
- AIDS Clinical Trials Group (ACTG)  
 275, 276
- AIDSInfoshare project, Moscow  
 185
- AIDSVAX  
 58, 153–167, 221, 223, 345
- antibodies  
*see also* neutralizing antibodies  
 10, 12, 31, 34, 46, 50–51, 53, 54,  
 55, 58, 67, 80, 89, 141, 155, 215,  
 266, 346

- antigen-presenting cells
  - 31, 33, 49, 346
- antiretroviral therapy/drugs (ARVs)
  - 61, 125, 126, 133, 138-139, 142-43, 191, 193, 196, 197, 221, 222, 223, 228, 346
- AIDS Vaccine Awareness Day
  - 88
- AIDS Vaccine Evaluation Units
  - 277
- attenuated vaccine
  - 27, 28, 346
- Bangkok Metropolitan Administration (BMA)
  - 164, 194
- Bangkok International AIDS Conference
  - 161, 191, 209, 223
- B-cells
  - 31, 34, 35, 46, 53, 54, 346
- Belmont Report
  - 105, 164
- bioterrorism
  - 5, 247
- booster
  - 48, 347
- Botswana
  - 205-211, 227, 297
- Brazil
  - 123-128, 147, 220, 244, 246, 256, 285, 285-292, 340
- breastfeeding
  - 55, 75, 91, 139
- bridging study
  - 215-217, 347
- British Columbia Center on HIV/AIDS Excellence
  - 194
- budding of HIV
  - 18, 19, 20
- Cameroon
  - 66, 67, 225
- Canada
  - 155, 216, 217, 244
- canarypox
  - 48, 49, 58, 290, 325, 347
- CD4+ T-cell, helper T-cell
  - 12, 19, 31, 33, 54, 55, 56, 57, 60-61, 74, 154, 156, 184, 206, 278, 347
- CD8+ T-cells, killer T-cell, cytotoxic lymphocytes (CTL)
  - 31, 34, 46, 54, 55, 56, 57, 347
- cellular immunity
  - cell-mediated immunity
    - 4, 11, 29, 31-35, 46, 47, 51, 53-58, 60, 67, 77, 83, 347
- challenge experiment
  - 39, 278, 348
- childhood vaccination
  - childhood immunization
    - 95, 100, 257-258
- China
  - iii, 64, 161, 246
- clade,
  - subtype
    - 63-69, 75, 129, 147, 149, 305, 325, 348
- commercial sex workers
  - see sex workers
- Community Advisory Board (CAB)
  - 93, 111, 117-122, 130, 133, 134, 136, 139, 141 148, 149, 177, 180, 189, 196, 206, 209, 240, 241, 248, 289, 290

- community education  
*see also* community preparedness  
 123-128, 170, 235
- community preparedness,  
 community readiness  
*see also* vaccine preparedness  
 129-136, 137-144, 196, 235, 236
- Council of International  
 Organizations for Medical Sciences  
 (CIOMS)  
 105
- cytokine  
 48, 83, 327, 349
- cytotoxic T-lymphocytes (CTL)  
*see* CD8+ T-cell
- Declaration of Helsinki  
 104, 105, 164
- delivery of vaccines  
 vi, 43, 244, 257, 268-271
- demand for vaccines  
 241, 250, 255
- diversity (genetic or viral)  
 13, 57, 63-70
- DNA vaccine  
 47-48, 324-325, 349
- education campaign  
*i-ii*, 43, 88, 220
- efficacy  
*see also* Phase IIb, Phase III trial  
 5, 11, 12, 40, 41, 42, 48, 51, 58,  
 68, 70, 150, 151, 201, 210, 213-217,  
 248, 256, 257, 277, 278
- Elispot  
 83
- env* (gene),  
 Env (protein),  
 envelope (of HIV)  
 16, 46, 48, 50, 65, 68, 155, 325,  
 327, 345, 348, 350, 351, 356, 358,  
 360
- epitope  
 56, 66, 67, 68, 325, 327, 350
- ethics  
 96, 99-100, 103-107, 108, 136, 138,  
 164, 166, 175, 177, 206, 243, 44
- Ethiopia  
 227, 244
- exposed seronegative (ESN)  
 55, 58, 187, 350
- female condom  
 67, 173
- fowlpox  
 325, 350
- gag* (gene),  
 Gag (protein)  
 16, 65, 68, 325, 327, 350, 361, 362
- Gates Foundation, Bill & Melinda  
 10, 245
- gay men  
 72, 75, 123, 153, 158, 198,  
 219-224, 276
- Gay Men's Health Crisis (GMHC)  
 220
- gender  
 120, 155, 159, 171-182
- Gender AIDS Forum (South Africa)  
 235
- genetic engineering  
 28, 45, 351
- genetic diversity  
*see* diversity
- GlaxoSmithKline (GSK)  
 213-214, 216-17

- Global Alliance for Vaccines and Immunization (GAVI)
  - 254
- Global Fund
  - 143, 191, 194
- global spending
  - global funding
  - v, 3, 8, 9, 222, 236, 257-258, 272
- Global Vaccine Enterprise
  - 10
- glycoprotein 41,
  - gp41
  - 16, 327, 351
- glycoprotein 120,
  - gp120
  - 16, 155, 279, 290, 325, 327, 345, 351, 356
- Good Clinical Practice (GCP)
  - 99, 150, 351
- Good Manufacturing Practice (GMP)
  - 150, 351
- Haiti
  - 90, 227
- harm reduction
  - 161, 191-194
- helper T-cell
  - see* CD4+ T-cell
- Hepatitis B vaccine
  - 27-28, 50, 53, 173, 216, 250
- Herpes simplex virus (HSV)
  - 159, 174, 184, 213, 216, 352
- HIV life cycle
  - 18
- HIV structure
  - 16
- HIV testing
  - see also* voluntary counseling and testing
  - 80, 111-112, 124, 139, 141, 143, 176, 194, 206, 226, 228
- HIV Vaccine Trials Network (HVTN)
  - 51, 122, 157, 203, 249, 325
- HIVNET
  - 129, 130, 221
- human papilloma virus (HPV)
  - 28, 213-216, 352
- human rights
  - 5, 133, 151, 179, 191, 195, 245, 287, 297
- humoral immunity
  - 29, 31, 34, 35, 46-47, 51, 352
- immune escape
  - 57, 352
- India
  - iii, 26, 64, 96, 161, 171, 174-178, 183, 186, 256, 271, 298
- informed consent
  - 73, 91, 96, 97, 99, 108, 109-116, 121, 125, 165, 176, 186, 200, 208, 221, 240, 241, 353
- injecting drug use(r) (IDU)
  - 72, 75, 161, 163-167, 190-197, 289
- Institutional Review Boards (IRBs)
  - 96, 100, 164, 353
- International AIDS Conference
  - see also* Bangkok International AIDS Conference
  - 202, 272, 293
- International AIDS Vaccine Initiative (IAVI)
  - 8, 47, 137, 149, 174, 175, 169, 241, 246, 247, 254

- Joint Clinical Research Center,  
Kampala, Uganda  
239
- Kenya  
142, 179, 225, 227
- Kenya AIDS Vaccine Initiative (KAVI)  
175, 180, 181
- killer T-cells  
*see* CD8+ T-cells
- KwaZulu-Natal, South Africa  
118, 129, 305
- Lesotho Positive Action  
1, 2
- licensure of vaccines  
11, 41-42, 58, 61, 74, 95, 97, 199,  
210, 247, 250, 256
- life cycle of HIV  
18
- lipopeptide  
49, 325, 326-327, 354
- live-vector vaccine  
48, 326-327, 354
- long-term non-progressors (LTNPs)  
26, 55, 354
- macrophage  
33
- manufacturing vaccines  
13, 40, 42-43, 64, 96, 250, 254,  
255-257
- March of Dimes  
265-266
- memory cells,  
immunological memory  
35, 56, 57, 354
- Merck & Co.  
58, 213-17
- microbicide  
67, 133, 173, 234-237, 246, 247,  
254, 355
- military  
225-230, 239, 240, 249
- monkey studies  
9, 12, 39, 48, 55
- mother-to-child transmission (MTCT)  
139, 142, 205
- Mozambique  
170, 227
- mucosal immunity  
12, 13, 29, 47, 51, 174, 355
- MVA (modified vaccinia Ankara)  
48, 325, 327, 355
- needle exchange  
193
- nef (gene),  
Nef (protein)  
68, 325, 327, 355, 359
- Nepal  
269
- neutralizing antibodies (NAb)  
12, 29, 46, 50, 67-68, 155, 355
- Nigeria  
225, 227, 246, 298
- NIH  
*see* US National Institutes of Health
- non-governmental organization (NGO)  
124, 125, 135, 174, 186, 191, 193,  
195, 220, 285-291
- Nuremberg Code  
104, 109, 164
- NYVAC  
327, 356
- oral vaccine  
14, 28, 49, 60, 260, 261, 267,  
268-271
- orphans  
135, 227, 239
- Pakistan  
269, 271

- partially effective vaccine
  - 3, 13, 52, 59–62, 125, 135, 250
- peptide
  - see also* lipopeptide
  - 47, 49, 290, 326–327, 356
- Peru
  - 231, 232
- Phase I trial
  - 36, 40, 41, 48, 51, 58, 69, 70, 71, 91, 97, 145, 149, 165, 179, 180, 228, 248, 278, 356
- Phase II trial
  - 40, 49, 225, 290, 357
- Phase IIb trial
  - proof-of-concept trial
  - 11, 36, 41, 58, 71, 74, 357
- Phase III trial
  - 40–41, 48, 50, 59, 68, 69, 71–75, 91, 97, 109, 150, 161, 163, 255, 357
- Phase IV trial
  - 41, 357
- placebo
  - 72, 73, 74, 91, 92, 97, 98, 99, 104, 156, 214, 240, 279, 357
- polio vaccine
  - 14, 25, 27, 28, 53, 60, 243, 260, 261, 262–272
- polio eradication
  - 260, 261, 262–272
- prime-boost
  - 77, 325, 358
- proof-of-concept trial
  - see* Phase IIb trial
- protocol
  - 96, 97, 106, 133, 149, 162, 164, 175, 177, 180, 195, 241, 278, 358
- regulatory approval,
  - regulatory agency
  - 40, 41, 42, 43, 74, 96, 99, 148, 207, 209, 210, 220, 236, 237, 249, 254, 255, 256
- Russia
  - Russian Federation
  - iii, 246, 248
- Rwanda
  - 227, 244
- safety
  - 39–41, 69, 71, 77, 87, 91, 95–102, 145, 147, 149, 207, 210, 215, 249
- sex worker (SW)
  - 26, 55, 183–189
- sexually transmitted disease (STD)
  - 28, 140, 174, 176, 183, 184, 180, 187, 208, 210, 213–217, 222, 254
- SHIV
  - simian/human immunodeficiency virus
  - 39, 360
- SIV
  - simian immunodeficiency virus
  - 9, 12, 39, 55, 278, 360
- smallpox
  - 25, 26, 27, 28, 48, 247
- South Africa
  - 1, 2, 6, 86, 129–136, 208, 220, 227, 228, 235, 248, 256, 293–298, 305–309
- South African AIDS Vaccine Initiative (SAAVI)
  - 129, 246
- South African HIV Vaccine Action Campaign (SA HVAC)
  - 108

- statistical analysis,
  - statistical significance
  - 15, 74, 153, 157, 159, 202, 360
- stigma
  - 4, 72, 87, 109, 123, 131, 139, 175, 176, 180, 184, 187, 189, 192, 201, 227, 241, 245, 250, 293-298
- structure of HIV
  - 16
- subtype
  - see* clade
- Sudan
  - 229, 270
- Tanzania
  - 77, 140, 170, 189, 225, 227, 244, 273, 274
- T-cells
  - see* CD4+ T-cells, CD8+ T-cells
- tenofovir
  - 195, 250
- Thai AIDS Treatment Action Group (TTAG)
  - 191
- Thai Drug Users Network (TDN)
  - 190-197
- Thailand
  - 48, 58, 66, 68, 69, 87-94, 150, 161-67, 190, 191-197, 212, 225, 244, 246-248, 298
- traditional healers
  - 118, 120
- Treatment Action Campaign (TAC)
  - 1-2, 294, 298
- trial volunteers
  - 5, 73, 87-93, 126, 127, 141, 143, 239-242, 299-309
- tuberculosis (TB)
  - 28, 143, 247
- Tuskegee
  - 301
- Uganda
  - 118, 145, 145-151, 227, 229, 239-241, 244, 293
- Ukraine
  - 246
- UNAIDS
  - vii, 96, 105, 110, 149, 161, 164, 166, 172, 207
- United Kingdom (UK)
  - 179, 247
- United Nations Special Assembly Special Session on AIDS (UNGASS)
  - 254
- US Army Medical Research Unit (USAMRU),
  - research program
  - 142, 225
- US Centers for Disease Control and Prevention (CDC)
  - 157, 164
- US Congress
  - 247
- US Food and Drug Administration (FDA)
  - 96, 97, 99, 100, 217
- US National Institute of Allergy and Infectious Diseases (NIAID)
  - 277
- US National Institutes of Health (NIH)
  - 129, 135, 147, 202, 203, 223, 225, 236, 246, 247, 325
- US President's Emergency Plan for AIDS Relief (PEPFAR)
  - 143
- Vaccine Fund, The
  - 254

- vaccine preparedness
  - 77, 129, 145, 163, 185, 221, 234, 236
- Vaccine Research Center (VRC)
  - 68, 244
- variation (genetic or viral)
  - see* diversity
- VaxGen
  - 58, 68, 73, 153–60, 161–167, 195, 201, 22
- VEE
  - Venezuelan encephalitis virus
    - 48, 299, 327, 361
- viral diversity
  - see* diversity
  - 63–70
- volunteers
  - see* trial volunteers
- voluntary counseling and testing (VCT)
  - v, 139, 143, 176, 226, 227
- Walter Reed Army Institute of Research (WRAIR)
  - 241
- World Health Organization (WHO)
  - vii, 28, 96, 129, 149 193, 210, 246, 249, 261
- World Medical Association (WMA)
  - 104
- Zimbabwe
  - 204